Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Highlights • There is a paucity of studies on therapies for the treatment of OB/BOS. • Pooled change in FEV1 with azithromycin was not statistically significant. • Current evidence cannot support or refute the use of azithromycin in this setting. • Further studies are needed to evaluate therapies fo...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2016-12, Vol.22 (12), p.2264-2269
Main Authors: Yadav, Hemang, Peters, Steve G, Keogh, Karina A, Hogan, William J, Erwin, Patricia J, West, Colin P, Kennedy, Cassie C
Format: Article
Language:English
Subjects:
Allogeneic
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Azithromycin - pharmacology
Azithromycin - therapeutic use
Bone marrow transplant
Bronchiolitis obliterans
Bronchiolitis Obliterans - drug therapy
Bronchiolitis Obliterans - etiology
Forced Expiratory Volume - drug effects
Hematology, Oncology and Palliative Medicine
Hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Obliterative bronchiolitis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • There is a paucity of studies on therapies for the treatment of OB/BOS. • Pooled change in FEV1 with azithromycin was not statistically significant. • Current evidence cannot support or refute the use of azithromycin in this setting. • Further studies are needed to evaluate therapies for OB/BOS after HSCT.
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2016.08.027